Presbia PLC (LENS) EPS Estimated At $-0.11

August 9, 2018 - By Margaret Guttierez

Investors sentiment increased to Infinity in 2018 Q1. Its up Infinity, from 0.67 in 2017Q4. It increased, as 0 investors sold Presbia PLC shares while 0 reduced holdings. 2 funds opened positions while 3 raised stakes. 5.31 million shares or 100.41% more from 2.65 million shares in 2017Q4 were reported.
Geode Capital Mngmt Limited Liability stated it has 0% of its portfolio in Presbia PLC (NASDAQ:LENS). Amundi Pioneer Asset Mngmt has invested 0% in Presbia PLC (NASDAQ:LENS). Moreover, Blackrock has 0% invested in Presbia PLC (NASDAQ:LENS). Fmr Limited Liability holds 2.57 million shares. Moreover, Vanguard Gp has 0% invested in Presbia PLC (NASDAQ:LENS) for 54,457 shares. Barclays Public Limited accumulated 59 shares or 0% of the stock. Morgan Stanley holds 2,382 shares or 0% of its portfolio. Commercial Bank Of America Corp De stated it has 686 shares or 0% of all its holdings. Royal Comml Bank Of Canada holds 0% of its portfolio in Presbia PLC (NASDAQ:LENS) for 2 shares.

Analysts expect Presbia PLC (NASDAQ:LENS) to report $-0.11 EPS on August, 10.They anticipate $0.16 EPS change or 59.26 % from last quarter’s $-0.27 EPS. After having $-0.12 EPS previously, Presbia PLC’s analysts see -8.33 % EPS growth. The stock decreased 2.30% or $0.05 during the last trading session, reaching $2.12. About 8,689 shares traded. Presbia PLC (NASDAQ:LENS) has declined 13.21% since August 9, 2017 and is downtrending. It has underperformed by 25.78% the S&P500.

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company has market cap of $36.37 million. The firm provides the refractive lens for patient surgeries, as well as accessories for procedures. It currently has negative earnings. It primarily operates in South Korea, Australia, the Netherlands, Ireland, and Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.